


**Figure S1. UFAs inhibit NLRP3 activation by non-classical inducers in PMA-differentiated THP-1 cells**

(**A**) IL-1β release in supernatants (SN) from PMA-differentiated THP-1 cells determined by immunoblotting after co-treatment with various NLRP3 inducers and 200 µM of UFAs or BSA. Cells were treated with doxorubicin (20 µM), antimycin A (25 µg/mL), tunicamycin (10 µg/mL), monensin (50 µM) or MDP (100 µg/mL) for8 h. (**B**) Quantification of IL-1β in SN from **A**. Results are presented as means ± SEM of at least three independent experiments. (**C**) IL-1β release in SN from PMA-differentiated THP-1 cells stably expressing shRNA against NLRP3 (shNLRP3) or a non-target shRNA (shNT) determined by immunoblotting after 8 h of treatment with either nigericin (5 µM), alum (400 µg/mL), MSU (100 µg/mL), antimycin A (25 µg/mL), doxorubicin (20 µM), MDP (100 µg/mL), monensin (50 µM), tunicamycin (10 µg/mL) or ATP (10 mM). NLRP3 was blotted as a control for shRNA. A non-specific band (NS) at 10 kDa was used as loading control in supernatants. HSP60 or HSP90 were blotted as a loading control in cell extracts. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; NS, non significant by *t*-test. XT, cell extract.